Innovodigm Secures Seed Funding to Transform Vaccine Delivery

Innovodigm has successfully raised Rs 5.5 crore in a seed funding round, primarily led by the IAN Group. IAN’s investment totals Rs 4.5 crore, with the balance provided by PadUp Ventures. This funding will be directed towards enhancing processes, scaling infrastructure, and expanding the team to facilitate third-party preclinical validation and prepare for future clinical trials.

About Innovodigm’s Innovative Approach to Vaccines

Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is pioneering the development of micro-array patches for vaccines. This approach offers a revolutionary alternative to conventional injectable immunization methods. The design addresses key issues such as dependency on cold-chain logistics, medical waste generation, and risks associated with needle-stick injuries. The micro-array patch (MAP) utilizes thermostabilized vaccines, which maintain their efficacy for up to 120 days at 40°C, thereby removing refrigeration requirements and facilitating access to remote and underserved communities.

Acknowledgements and Recognition

Innovodigm’s MAP platform has received significant acclaim, including being ranked among the Top 2 Technologies at the Nano Electronics Showcase 2025, recognized by the Ministry of Electronics & IT. Furthermore, the company has established a Material Transfer Agreement (MTA) with a prominent Indian vaccine manufacturer for third-party validation, with clinical trials slated to begin next year.

Vision for the Future

Jhimli Manna, CEO of Innovodigm, stated that the company’s roots are deeply embedded in IIT Kharagpur’s Microelectronics and MEMS Lab, which has been pivotal to their scientific breakthroughs. Their MAP platform embodies India’s potential to excel in providing affordable, scalable vaccine delivery solutions that align with both national and global public health objectives.

Innovodigm plans to extend its reach across India and into other low- and middle-income nations, with aims to adapt the patch for various vaccines, such as measles, hepatitis, flu, and COVID-19 boosters. Additionally, the company is focused on establishing local manufacturing hubs, ensuring that patches are produced close to the areas of greatest need.